BERLIN, Germany and SEATTLE, March 13, 2008 (PRIME NEWSWIRE) -- Epigenomics AG (Frankfurt:ECX), a cancer molecular diagnostics company, will hold its annual press conference and analyst meeting on Monday, March 31, 2008 and present results for the fiscal year 2007. Geert Walther Nygaard, CEO and Oliver Schacht, CFO will give an overview of the operational developments as well as provide guidance for 2008. A conference call with Epigenomics' management will be held later on the same day.
Press Conference and Analyst Meeting
The press conference and analyst meeting will be conducted in German and will be held on Monday, March 31, 2008 from 10 a.m. to 12 noon CET at the premises of the Villa Bonn - Frankfurter Gesellschaft fur Handel Industrie und Wirtschaft in Frankfurt am Main:
Villa Bonn Frankfurter Gesellschaft fur Handel Industrie und Wirtschaft Siesmayerstrasse 12 60323 Frankfurt am Main
Room: Vortragsraum (OG)
Epigenomics asks interested parties to confirm their participation for the press conference and analyst meeting by Thursday, March 27, 2008 by fax, +49 (0)30 24 34 5- 555 or email, ir@epigenomics.com.
Conference Call
A conference call will be held on Monday, March 31, 2008 from 3 p.m. to 4 p.m. CET (9 a.m. to 10 a.m. EST), hosted by Epigenomics' management to discuss 2007 financial results and outlook for 2008. The conference call will be conducted in English.
Dial-in number (within Germany.): +49 (0) 6103 485 3001 Dial-in number (outside Germany): +1 480 629 1990
Please dial-in at least 10 minutes prior to commencement of the conference call.
To follow the presentation, Epigenomics kindly asks all participants of the call to download the slide set from the company website prior to the call where it will be made available as a PDF file at 10 a.m. CET (4 a.m. EST) on the same day.
Internet link: http://www.epigenomics.com/en/down_loads/corporate_material/
The conference call will be recorded and also made available on the company website web as a MP3 file after the call.
Internet link: http://www.epigenomics.com/en/down_loads/corporate_material/
About Epigenomics
Epigenomics is a molecular diagnostics company with a focus on the development of novel products for cancer. Using DNA methylation biomarkers, Epigenomics' tests can potentially diagnose cancer at an early stage and help guide physicians to select an appropriate therapy. Epigenomics' defined business strategy covers two complementary core business areas:
The company develops diagnostic screening tests for the early detection of cancer. Based on body fluid samples (e.g. blood and urine), these tests are aimed at finding cancer at an early stage before symptoms occur. Epigenomics' product pipeline contains a validated biomarker panel for the early detection of colorectal cancer in blood plasma, and further proprietary DNA methylation biomarkers at various stages of development for prostate and lung cancer detection in body fluids. For development and global commercialization as in vitro diagnostic test kits, Epigenomics pursues a non-exclusive partnering strategy with diagnostics industry companies. As a first strategic partner, Abbott Molecular Inc. licensed the worldwide non-exclusive rights to Epigenomics' proprietary Septin 9 biomarker for colorectal cancer. Epigenomics also aims at giving patients and doctors early access to these biomarkers through reference laboratory testing services. As a first reference laboratory partner, Quest Diagnostics Inc., the leading provider of diagnostic testing, information and services, obtained the license to commercialize a laboratory-developed test (LDT) for Septin 9 in the U.S.
As a second core business area, Epigenomics develops specialty diagnostics for individuals at high risk for cancer and cancer patients. These tests include surveillance applications of our colorectal cancer biomarkers and a tissue-based prognostic cancer molecular classification test for prostate cancer patients. Our tissue-based prostate cancer application is developed in strategic partnerships with Qiagen GmbH (pre-analytics) and Affymetrix, Inc. (diagnostic device platform). The biomarkers for cancer specialty diagnostic applications will be made available through testing services in centralized reference laboratories. Epigenomics retains the flexibility to decide on further commercialization as in vitro diagnostic test kits in Europe.
Pharma, diagnostics and biotech partners can access Epigenomics' portfolio of proprietary DNA methylation technologies and biomarkers protected by more than 150 patent families (granted patents and patent applications) through Biomarker Services, IVD Development Collaborations, and Licensing. The company is headquartered in Berlin, Germany, and has a wholly owned subsidiary in Seattle, WA, USA. For more information, please visit Epigenomics' website at www.epigenomics.com.
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.